1. Home
  2. HYNE vs PYXS Comparison

HYNE vs PYXS Comparison

Compare HYNE & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HYNE

Hoyne Bancorp Inc.

N/A

Current Price

$16.20

Market Cap

116.5M

Sector

Finance

ML Signal

N/A

Logo Pyxis Oncology Inc.

PYXS

Pyxis Oncology Inc.

HOLD

Current Price

$1.79

Market Cap

124.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HYNE
PYXS
Founded
2025
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
116.5M
124.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
HYNE
PYXS
Price
$16.20
$1.79
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$7.00
AVG Volume (30 Days)
19.1K
744.5K
Earning Date
05-14-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
3.03
EPS
N/A
N/A
Revenue
N/A
$13,858,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$7,043.98
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.56
$0.97
52 Week High
$16.14
$5.55

Technical Indicators

Market Signals
Indicator
HYNE
PYXS
Relative Strength Index (RSI) 66.93 45.57
Support Level $15.51 $1.23
Resistance Level N/A $2.27
Average True Range (ATR) 0.17 0.25
MACD 0.02 -0.07
Stochastic Oscillator 89.55 18.89

Price Performance

Historical Comparison
HYNE
PYXS

About HYNE Hoyne Bancorp Inc.

Hoyne Bancorp Inc is a holding company that conducts business mainly through its subsidiaries. It is a savings institution focused on serving customers' banking needs in the market area. The group offers Personal and Business banking services.

About PYXS Pyxis Oncology Inc.

Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.

Share on Social Networks: